ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Prostate Related Issues
Persistent T Suppression After Cessation of ADT for Localized PCa
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="madman" data-source="post: 223324" data-attributes="member: 13851"><p><h3>Introduction</h3><p></p><p><strong>Persistent Testosterone Suppression After Cessation of Androgen Deprivation Therapy for Localized Prostate Cancer (2022)</strong></p><p><em>JDelgado, JOry, JBitran, RBlachman Braun ,SNackeeran, RRamasam</em></p><p></p><p></p><p><strong>Introduction</strong></p><p></p><p><em>ADT plays a fundamental role in the treatment of localized prostate cancer. However, there is limited data regarding testosterone recovery in men who have received ADT for prostate cancer. Identification of T recovery profiles associated with ADTs will facilitate the personalization of ADT regimens and guide future treatment strategies to minimize the risk of T deficiency in patients with prostate cancer.</em></p><p></p><p></p><p><strong>Objective</strong></p><p></p><p><em>Temporary use of Androgen Deprivation Therapy (ADT) is a cornerstone in the treatment of localized prostate cancer. However, the ability of testosterone to recover after ADT is not well understood. <strong>The aim of this study was to investigate testosterone recovery in men with prostate cancer following varying ADT modalities and treatment durations.</strong></em></p><p></p><p></p><p><strong>Methods</strong></p><p></p><p><em><strong>A global federated health research network (TriNetX) was used to identify men with a diagnosis of prostate cancer who underwent temporary use of ADT. Three cohorts were identified: Men who received LHRH antagonists, LHRH agonists, and men who received combined ADT (LHRH agonist and antiandrogens). Further stratification was based on treatment duration of 6 or 18 months to compare T recovery profiles at follow-up periods of 2 and 5 years.</strong></em></p><p></p><p></p><p><strong>Results</strong></p><p></p><p><em>A total of 17,884 men received LHRH agonists alone, 12,767 men received combined ADT, and 628 men received LHRH antagonist therapy alone. <strong>Eugondal mean baseline T level (>300 ng/dL) prior to starting ADT was an inclusion criterion for all men. Five years after ADT cessation, 36% of patients who received LHRH agonists recovered eugonadal T levels, 26% recovered after LHRH antagonist therapy, and 36.8% recovered after combined ADT. Overall, more than half of men who received ADT failed to recover eugonadal T levels even 5 years after treatment cessation.</strong></em></p><p></p><p></p><p><strong>Conclusions</strong></p><p><strong></strong></p><p><strong><em>Five years after ADT cessation, incomplete testosterone recovery persists in more than 50% of men. Testosterone deficiency will lead to metabolically adverse changes in body composition, increased insulin resistance, impaired bone health, and poor quality of life and needs to be evaluated even after cessation of ADT.</em></strong></p></blockquote><p></p>
[QUOTE="madman, post: 223324, member: 13851"] [HEADING=2]Introduction[/HEADING] [B]Persistent Testosterone Suppression After Cessation of Androgen Deprivation Therapy for Localized Prostate Cancer (2022)[/B] [I]JDelgado, JOry, JBitran, RBlachman Braun ,SNackeeran, RRamasam[/I] [B]Introduction[/B] [I]ADT plays a fundamental role in the treatment of localized prostate cancer. However, there is limited data regarding testosterone recovery in men who have received ADT for prostate cancer. Identification of T recovery profiles associated with ADTs will facilitate the personalization of ADT regimens and guide future treatment strategies to minimize the risk of T deficiency in patients with prostate cancer.[/I] [B]Objective[/B] [I]Temporary use of Androgen Deprivation Therapy (ADT) is a cornerstone in the treatment of localized prostate cancer. However, the ability of testosterone to recover after ADT is not well understood. [B]The aim of this study was to investigate testosterone recovery in men with prostate cancer following varying ADT modalities and treatment durations.[/B][/I] [B]Methods[/B] [I][B]A global federated health research network (TriNetX) was used to identify men with a diagnosis of prostate cancer who underwent temporary use of ADT. Three cohorts were identified: Men who received LHRH antagonists, LHRH agonists, and men who received combined ADT (LHRH agonist and antiandrogens). Further stratification was based on treatment duration of 6 or 18 months to compare T recovery profiles at follow-up periods of 2 and 5 years.[/B][/I] [B]Results[/B] [I]A total of 17,884 men received LHRH agonists alone, 12,767 men received combined ADT, and 628 men received LHRH antagonist therapy alone. [B]Eugondal mean baseline T level (>300 ng/dL) prior to starting ADT was an inclusion criterion for all men. Five years after ADT cessation, 36% of patients who received LHRH agonists recovered eugonadal T levels, 26% recovered after LHRH antagonist therapy, and 36.8% recovered after combined ADT. Overall, more than half of men who received ADT failed to recover eugonadal T levels even 5 years after treatment cessation.[/B][/I] [B]Conclusions [I]Five years after ADT cessation, incomplete testosterone recovery persists in more than 50% of men. Testosterone deficiency will lead to metabolically adverse changes in body composition, increased insulin resistance, impaired bone health, and poor quality of life and needs to be evaluated even after cessation of ADT.[/I][/B] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Prostate Related Issues
Persistent T Suppression After Cessation of ADT for Localized PCa
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top